On May 29, 2018 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, reported it will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 (Press release, AbbVie, MAY 29, 2018, View Source [SID1234527051]). Richard A. Gonzalez, chairman and chief executive officer, will present at 10 a.m. Central time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

On May 29, 2018 BerGenBio ASA (OSE: BGBIO) reported it will host a conference call on Monday, 4 June at 8:30 AM CEST to present updated interim clinical and biomarker results from its ongoing Phase II development programme with selective AXL inhibitor bemcentinib (Press release, BerGenBio, MAY 29, 2018, View Source [SID1234527034]). The data will be presented at the Annual American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) meeting and at a reception hosted by BerGenBio (details below).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call details:
The call will be hosted by BerGenBio senior management and take place on:
Monday, 4 June 2018 at 8:30 AM CEST.
To take part, please dial in 5-10 minutes prior to the scheduled start using below phone number and confirmation code 1068189:

Norway +47 2100 2608
United Kingdom +44 (0)330 336 9106
United States +1 323-794-2594

A slide deck presentation to accompany the call will be made available at www.bergenbio.com in the Investors / Presentations section from 8:00 AM CEST on 4 June 2018.

Presentations to be made during the annual ASCO (Free ASCO Whitepaper) meeting:
Saturday 2 June, 6:00 – 8:00 PM CDT, Chicago School of the Art Institute, Chicago, IL
BerGenBio private reception

New interim Phase II clinical trial data with bemcentinib and selected pre-clinical data to be discussed by BerGenBio principal investigators and invited key opinion leaders
For further details and to receive an invitation, please click here
Monday 4 June, 8:00 AM – 11:30 AM CDT, ASCO (Free ASCO Whitepaper) Annual Meeting, McCormick Center, Chicago, IL

Interim clinical data from clinical trial ref. BGBC008 – Poster Board: #292, Abstract 3078
Interim clinical data from clinical trial ref. BGBC003 – Poster Board: #80, Abstract 7020
To be discussed at the Poster Discussion Session. 11:30 AM – 12:45 PM
Biomarker study – Poster Board: #385, Abstract 2559
Monday 4 June, 1:15 PM – 4:45 PM CDT, ASCO (Free ASCO Whitepaper) Annual Meeting, McCormick Center, Chicago, IL

Interim clinical data from clinical trial ref. BGBIL006 – Poster Board: #375, Abstract 9548
The posters presented at ASCO (Free ASCO Whitepaper) will be made available www.bergenbio.com in the Investors / Presentations section at the time of presentation.

On May 29, 2018 Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, reported that Isaac Ciechanover, M.D., the Company’s President and Chief Executive Officer, will participate at two upcoming investor conferences in June (Press release, Atara Biotherapeutics, 29 29, 2018, View Source [SID1234526936]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2018 Global Healthcare Conference
Company Presentation: Tuesday, June 5, 2018 at 11:00 a.m. ET
Grand Hyatt in New York, NY

Goldman Sachs 39th Annual Global Healthcare Conference
Fireside Chat: Tuesday, June 12, 2018 at 1:20 p.m. PT
Terranea Resort in Rancho Palos Verdes, CA

Live audio webcasts of the presentations will be available by visiting the Investors section of the Atara website at www.atarabio.com. Archived replays of the webcasts will be available on the Company’s website for 14 days following each presentation.

On May 29, 2018 Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, reported that Isaac Ciechanover, M.D., the Company’s President and Chief Executive Officer, will participate at two upcoming investor conferences in June (Press release, Atara Biotherapeutics, MAY 29, 2018, View Source [SID1234526936]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2018 Global Healthcare Conference
Company Presentation: Tuesday, June 5, 2018 at 11:00 a.m. ET
Grand Hyatt in New York, NY

Goldman Sachs 39th Annual Global Healthcare Conference
Fireside Chat: Tuesday, June 12, 2018 at 1:20 p.m. PT
Terranea Resort in Rancho Palos Verdes, CA

Live audio webcasts of the presentations will be available by visiting the Investors section of the Atara website at www.atarabio.com. Archived replays of the webcasts will be available on the Company’s website for 14 days following each presentation.

On May 29, 2018 Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018, at 2:00 p.m. EDT at the Grand Hyatt New York Hotel (Press release, Heron Therapeutics, MAY 29, 2018, View Source [SID1234526934]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of this presentation will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.